A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis-Reference-Cited by-同舟云学术

A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis

Published:2002-02 Issue:1 Volume:47 Page:29-35
ISSN:0004-3591
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Hernández-Rodríguez José,García-Martínez Ana,Casademont Jordi,Filella Xavier,Esteban María-José,López-Soto Alfonso,Fernández-Solà Joaquim,Urbano-Márquez Álvaro,Grau Josep M.,Cid Maria C.

Funder

Fondo de Investigación Sanitaria

Fundació Pedro Pons

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference44 articles.

1. Giant cell arteritis and polymyalgia rheumatica;Hunder;Med Clin North Am,1997

2. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell arteritis;Cid;Arthritis Rheum,1997

3. The acute phase response;Baumann;Immunol Today,1994

4. Acute-phase proteins and other systemic responses to inflammation;Gabay;N Engl J Med,1999

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Limb arteries involvement assessed by FDG/PET CT at diagnosis of giant cell arteritis and risk of relapse: An observational study;Joint Bone Spine;2024-09

2. Relapses in giant cell arteritis: Updated review for clinical practice;Autoimmunity Reviews;2024-06

3. Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis;Rheumatology International;2024-02-01

4. Giant-cell arteritis related strokes: scoping review of mechanisms and rethinking treatment strategy?;Frontiers in Neurology;2023-12-07

5. Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study;The Lancet Rheumatology;2023-12